Back to School: How biopharma can reboot drug development. Access exclusive analysis here
AVAN and Celldex (Phillipsburg, N.J.) will merge in a stock deal that values the combined company at $115 million based on AVAN's
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury